CXCL8 and triple-negative breast carcinoma: IL-8 is associated with a worse clinical outcome in STEMI.21 As far as we know, no studies have addressed the effect of tocilizumab on IL-8 in MI, but it has been observed that tocilizumab is a potent inhibitor of IL-8 in triple-negative breast cancer.22 In this study, however, we showed a significant increase in IL-8 levels in the tocilizumab group, particularly in those presenting ≤3 hours from symptom onset.